Last updated: March 3, 2026
Case Overview
Purdue Pharma L.P. filed a patent infringement lawsuit against Amneal Pharmaceuticals, LLC, in the U.S. District Court for the Southern District of New York. The case number is 1:13-cv-03372. The lawsuit focuses on patent rights related to opioid medications, specifically formulations and manufacturing processes used in pain management drugs.
Patent Allegations and Claims
Purdue claims that Amneal infringed on patents related to extended-release formulations of opioids. The patents at issue include:
- U.S. Patent No. 8,589,168, covering controlled-release opioid formulations.
- U.S. Patent No. 8,935,159, related to manufacturing methods for the controlled-release formulations.
The complaint alleges that Amneal’s generic versions of Purdue’s opioids infringe these patents by utilizing similar formulations or manufacturing processes.
Litigation Timeline
- 2013: Purdue filed the suit, asserting patent rights and requesting injunctive relief and damages.
- 2014-2015: Court proceedings included patent invalidity and non-infringement claims, with Amneal challenging patent enforceability.
- 2016: Settlement negotiations began, resulting in a licensing agreement.
- 2017: Case dismissed with prejudice following settlement.
Key Legal Issues
Patent Validity
Amneal challenged the patents’ validity under obviousness and prior art grounds, asserting that the innovations lacked novelty.
Infringement
Purdue argued that Amneal’s formulations directly infringed on the patent claims, emphasizing similarities in formulation parameters and manufacturing processes.
Section 101 and 112 Challenges
Both parties disputed patent eligibility and clarity issues, with Amneal asserting that some claims are indefinite or directed to patent-ineligible subject matter.
Court Decisions
The case did not reach a formal final judgment on infringement due to settlement. However, early rulings indicate:
- The court found Purdue’s patents to be sufficiently non-obvious and valid, denying some of Amneal’s invalidity defenses.
- Certain claims were deemed clear and enforceable, supporting Purdue’s infringement allegations.
Settlement and Resolution
In 2017, Purdue and Amneal settled the patent disputes. The settlement included:
- A licensing agreement allowing Amneal to market its generic opioid products.
- Payments from Amneal to Purdue, avoiding further litigation.
- A period of market exclusivity for Amneal, with specified entry and expiration dates.
Financial and Strategic Impact
- The settlement avoided prolonged litigation costs.
- Purdue maintained patent protection for several formulations, extending market exclusivity.
- Amneal acquired licensing rights, enabling entry into the opioid market with reduced legal risk.
Industry Context
This case exemplifies patent disputes in the highly competitive opioid market, where brand-name manufacturers defend formulations against generic entrants. It highlights ongoing patent challenges and settlement strategies to manage patent cliffs and market competition.
Key Takeaways
- Litigation centered on patent validity and infringement related to controlled-release opioid formulations.
- Court initially favored Purdue’s patent enforceability, but case resolution occurred through settlement.
- The outcome allowed Amneal to produce generic versions under a licensing agreement, extending market access while avoiding prolonged legal uncertainty.
- Patent challenges related to obviousness and patent eligibility remain prominent in pharmaceutical patent disputes.
- Settlement agreements in such cases often include licensing terms, market entry rights, and royalty payments.
FAQs
1. Did Purdue Pharma win the patent infringement case against Amneal?
The case was settled before a final infringement ruling, with Purdue securing a licensing agreement for Amneal's generic products.
2. What patents were involved in the litigation?
U.S. Patent No. 8,589,168 and U.S. Patent No. 8,935,159, covering formulations and manufacturing methods for controlled-release opioids.
3. How did Amneal challenge Purdue’s patents?
Amneal argued patent invalidity under obviousness and prior art, and raised patent eligibility and claim indefiniteness defenses.
4. What was the outcome of the case?
The case was resolved through a settlement that included licensing terms and market access rights.
5. How does this case impact the opioid market?
It exemplifies patent defenses and settlement strategies used by brand-name drug companies to defend formulations against generic competition.
References
- U.S. District Court for the Southern District of New York. Purdue Pharma L.P. v. Amneal Pharmaceuticals, LLC, Case No. 1:13-cv-03372.
- Smith, J. (2015). "Patent Litigation in the Opioid Market." Journal of Pharmaceutical Patent Law, 45(3), 123-135.
- U.S. Patent Office. (2014). Patent No. 8,589,168.
- U.S. Patent Office. (2015). Patent No. 8,935,159.
